Avoids drug-induced "buzz" or "high" TRANXENE starts working promptly-yet with no reports Helps avoid effects that encourage drug-seeking behavior Helps avoid disruptive effects of therapy Eight years of clinical experience demonstrate that Reference is made to my telephone conversation with Dr. David Scally The following changes are being made to help clarify the use of 34 FFL 2) HOFFMANN-LA ROCHE INC • NUTLEY • NEW JERSEY Division of Neuropharmacological Drug Products June 20, 1986 Page 2 Please note that the dosage per se has not been revised. The attached revised language of the package insert was discussed with Dr. Scally on May 15 and he concurs with the revision. These editorial revisions are being made to provide more succinct directions for use and to help prevent the possibility of one starting titration with a dose of 0.1 to 0.15 mg/kg rather than titrating the dosage to this endpoint. Also, the time period over which titration should take place is further clarified. In accordance with 21 CFR §314.70(c)(2)(iii), these changes are being effected immediately. All stock packaged on or after July 15, 1986 will bear the revised insert (date code 0686). All promotional materials currently being prepared reflect this package insert revision. Twelve copies of final printed labeling are enclosed herein. |